Tim Hopper, MBA
Helping Medical Device/Drug Delivery Companies Accelerate Commercialization Timelines | Bringing Napkin Sketches to Life
October 2015
< 1 min reading time
The boundaries between the traditional drug and medtech realms are gradually eroding, being redrawn, and then eroding again. Blurred Lines: Big Pharma’s On-Again Off-Again Relationship with Medtech | QmedThe boundaries between the traditional drug and medtech realms are gradually eroding, being redrawn, and then eroding again. source: https://www.linkedin.com/groups/78665/78665-6057576999977840643 Marked as spam
|
Meet your next client here. Join our medical devices group community.
|
|
Private answer
Brian K. Buntz
Thanks, Marrianne. I learned a lot myself about the relationship between pharma and medtech in my interview with the EG-GILERO folks.
Marked as spam
|
|
Private answer
Brian K. Buntz
The notion of implantable devices that gradually deliver drugs for, say, 6 months at a time is interesting. Wonder how popular that type of technology will be ultimately? On the one hand, users don't have to take pills every day; on the other, you have to have a new implant put in every 6 months for as long as you are taking the course of medicine.
Marked as spam
|
|
Private answer
Edward Dolan
Brian and George both make very good points. At an MDG symposium on combination products 2 years ago, Andrew von Eschenbach made the point that the future is building on a basketball model, not a golf model: collaboration across disciplines, not solo heroes.
Marked as spam
|